Siddiqui, B. A., Basu, S., Jindal, S., Zhang, M., Zhu, K., Troncoso, P., Sandigursky, S., Miller, E., Skokos, D., Moesta, A., Mezzancello, M., Seebach, F. A., Lowy, I., Tidwell, R. S., Sharma, P., Subudhi, S. K. (2026). Hypervigilance: A phase Ib clinical trial to optimize risk-benefit of nezastomig (PSMAxCD28 costimulatory bispecific antibody) plus cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.tps295